Blurbs

Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), CASI Pharmaceuticals (CASI) and Arcus Biosciences (RCUS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Labs (ABTResearch Report), CASI Pharmaceuticals (CASIResearch Report) and Arcus Biosciences (RCUSResearch Report) with bullish sentiments.

Abbott Labs (ABT)

In a report released yesterday, Marie Thibault from BTIG maintained a Buy rating on Abbott Labs, with a price target of $138.00. The company’s shares closed last Monday at $119.99.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 20.4% and a 38.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Labs with a $143.22 average price target.

See Insiders’ Hot Stocks on TipRanks >>

CASI Pharmaceuticals (CASI)

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on CASI Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Monday at $0.91.

According to TipRanks.com, Zelin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.1% and a 29.2% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, Viking Therapeutics, and Surface Oncology.

CASI Pharmaceuticals has an analyst consensus of Moderate Buy.

Arcus Biosciences (RCUS)

BTIG analyst Kaveri Pohlman maintained a Buy rating on Arcus Biosciences yesterday and set a price target of $70.00. The company’s shares closed last Monday at $36.50.

According to TipRanks.com, Pohlman has 0 stars on 0-5 stars ranking scale with an average return of -32.1% and a 13.9% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Oncternal Therapeutics, and Mersana Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $59.50 average price target, which is a 65.5% upside from current levels. In a report issued on March 15, Citigroup also maintained a Buy rating on the stock with a $48.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos